## **AMENDMENTS TO THE CLAIMS**

This listing of Claims will replace all prior versions, and listings, of claims in the application:

## Listing of Claims:

1. (original) A compound having Formula I, or a pharmaceutically acceptable salt thereof, wherein

R<sup>1</sup> and R<sup>2</sup> are each C<sub>1</sub>-C<sub>3</sub> alkyl, which are optionally substituted with 1-5 halogens independently selected from F and Cl;

R3 is selected from the group consisting of

- (a) H, and
- (b) C<sub>1</sub>-C<sub>3</sub>alkyl, which is optionally substituted with 1-5 halogens independently selected from F and Cl;

R<sup>4</sup> is C<sub>1</sub>-C<sub>3</sub> alkyl, which is optionally substituted with 1-5 halogens independently selected from F and Cl;

 $R^5$  is selected from the group consisting of H and C<sub>1</sub>-C<sub>3</sub>alkyl, which is optionally substituted with 1-5 halogens independently selected from F and Cl;

R6 is selected from H, Cl, CH3 and CF3;

 $R^7$  is selected from H and  $C_1$ - $C_3$  alkyl, which is optionally substituted with 1-5 halogens independently selected from F and Cl;

A and B are each selected from H, Cl, F, CH3, and CF3;

The dashed line connecting the ring carbon atoms attached to R<sup>5</sup> and R<sup>7</sup> is an optional double bond;

X and Y are independently selected from O and S; and

Serial No.: 10/522,646 Case No.: 21173P Page 5

n is an integer from 2-3.

- 2. (original) A compound according to Claim 1, wherein X and Y are each O.
- 3. (original) A compound according to Claim 1, wherein A, B, and R<sup>7</sup> are H.
- 4. (original) A compound according to Claim 1, wherein R<sup>5</sup> is CF<sub>3</sub>.
- 5. (original) A compound according to Claim 1, wherein R<sup>5</sup> is C<sub>1</sub>-C<sub>3</sub> alkyl.
- 6. (original) A compound according to Claim 1, wherein R<sup>6</sup> is selected from Cl, CH<sub>3</sub> and CF<sub>3</sub>.
- 7. (original) A compound according to Claim 6, wherein R<sup>6</sup> is Cl.
- 8. (original) A compound according to Claim 1, wherein R<sup>3</sup> and R<sup>4</sup> are each independently selected from CH<sub>3</sub>, C<sub>2</sub>H<sub>5</sub>, and C<sub>3</sub>H<sub>7</sub>.
- 9. (original) A compound according to Claim 1, wherein R<sup>1</sup> and R<sup>2</sup> are each selected from CH<sub>3</sub> and C<sub>2</sub>H<sub>5</sub>.
- 10. (original) A compound according to Claim 9, wherein R<sup>1</sup> and R<sup>2</sup> are each CH<sub>3</sub>.
- 11. (original) A compound according to Claim 1, wherein

 $R^1$  and  $R^2$  are each independently selected from the group consisting of CH3 and  $C_2H_5$ :

R3 and R4 are each independently selected from the group consisting of CH3, C2H5, and C3H7;

 $R^5$  is CF3;

R6 is Cl;

R<sup>7</sup>, A, and B are H;

The dashed line connecting the ring carbon atoms attached to R5 and R7 is a double bond;

Serial No.: Case No.: 10/522,646 21173P

Page

6

X and Y are O; and

n is an integer from 2-3.

- 12. (original) A compound according to Claim 11, wherein R<sup>1</sup> and R<sup>2</sup> are each CH<sub>3</sub>.
- 13. (original) A compound according to Claim 1, having the formula shown below, or a pharmaceutically acceptable salt thereof:

Serial No.: Case No.: 10/522,646

Page

21173P

14. (original) A pharmaceutical composition comprising a compound of Claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

## Claim 15 cancelled

16. (original) A method for treating one or more lipid disorders, selected from the group consisting of dyslipidemia, hypercholesterolemia, hyperlipidemia, hypertriglyceridemia,

Serial No.: 10/522,646 Case No.: 21173P

Page

low HDL levels, and high LDL levels in a patient in need of such treatment which comprises administering to said patient a therapeutically effective amount of a compound of Claim 1.

Claims 17-28 cancelled